scholarly journals QuickStats: Prevalence* of Past or Present Infection with Hepatitis B Virus† Among Adults Aged ≥18 Years, by Race and Hispanic Origin — National Health and Nutrition Examination Survey, 1999–2018

2020 ◽  
Vol 69 (35) ◽  
pp. 1231
2019 ◽  
Vol 70 (12) ◽  
pp. 2619-2627 ◽  
Author(s):  
Jaimie Z Shing ◽  
Kathleen N Ly ◽  
Jian Xing ◽  
Eyasu H Teshale ◽  
Ruth B Jiles

Abstract Background Hepatitis B virus (HBV) can transmit through needle sharing. The national HBV infection prevalence in persons who inject drugs remains ill-defined. We estimated the prevalence of total HBV core antibody (anti-HBc) positivity, indicating a previous or ongoing HBV infection, among adults aged 20–59 years with an injection drug use (IDU) history. We compared select characteristics by anti-HBc status. Methods Using 2001–2016 National Health and Nutrition Examination Survey data, we calculated the anti-HBc positivity prevalence among adults with IDU histories and among the general US population. For adults with IDU histories, we compared sex, age group, birth cohort, race/ethnicity, health insurance coverage, and hepatitis A immunity by anti-HBc status. Using marginal structural models, we calculated model-adjusted prevalence rates and ratios to determine the characteristics associated with anti-HBc positivity among adults with IDU histories. Results From 2001–2016, the anti-HBc positivity prevalence was 19.7% (95% confidence interval [CI] 16.0–24.0%) among those with IDU histories, compared with 4.6% (95% CI 4.3–5.0%) in the general population. The HBV surface antigen positivity prevalence was 0.4% (95% CI 0.3–0.5%) in the general population. Among adults with IDU histories, 19.8% reported prior-year IDU and 28.5% had a hepatitis A immunity. Conclusions One-fifth of adults with IDU histories had a previous or ongoing HBV infection: a rate over 4 times higher than the prevalence in the general population. One-fifth of adults with IDU histories reported prior-year use. Programs promoting safe IDU practices, drug treatment, and hepatitis A and B vaccinations should be key components of viral hepatitis prevention.


1998 ◽  
Vol 178 (4) ◽  
pp. 954-959 ◽  
Author(s):  
Patrick J. Coleman ◽  
Geraldine M. McQuillan ◽  
Linda A. Moyer ◽  
Stephen B. Lambert ◽  
Harold S. Margolis

2013 ◽  
Vol 103 (10) ◽  
pp. 1865-1873 ◽  
Author(s):  
Maxine M. Denniston ◽  
Kathy K. Byrd ◽  
R. Monina Klevens ◽  
Jan Drobeniuc ◽  
Saleem Kamili ◽  
...  

Diseases ◽  
2020 ◽  
Vol 8 (2) ◽  
pp. 10
Author(s):  
Azad R. Bhuiyan ◽  
Nusrat Kabir ◽  
Amal K. Mitra ◽  
Oluwabunmi Ogungbe ◽  
Marinelle Payton

Hepatitis B virus (HBV) infection is the most common form of viral hepatitis and remains a global public health problem, even though the HBV vaccine is available. HBV leads to chronic liver disease, including cirrhosis, liver cancer, and death. This study aimed to identify disparities in HBV vaccine coverage with the serological test by race/ethnicity, adjusting for gender and age. In this study, 5735 adult participants were included, obtaining data from the National Health and Nutrition Examination Survey (NHANES), 2015–2016. Proc survey frequency, bivariate- and multivariate logistic regression in the weighted sample were performed due to the complex survey design of NHANES. Data were analyzed using SAS, version 9.2.4. The overall prevalence of HBV vaccine coverage was only 23.3% (95% CI: 20.7%, 25.9%). In a multivariate logistic regression model, data showed that Mexican Americans (OR 0.57, 95% CI: 0.38, 0.86) and African Americans (OR 0.70, 95% CI 0.56, 0.84) had lower vaccine coverage compared to Whites. Females had (OR 1.55, 95% CI: 1.30, 1.85) higher vaccine coverage compared to men. Older age groups (30–49 years) (OR 0.41, 95% CI: 0.32, 0.52) and age group ≥ 50 years (OR 0.18, 95% CI 0.14, 0.23) had lower vaccine coverage compared to younger adults aged 18–29 years.


Sign in / Sign up

Export Citation Format

Share Document